Nemaura Medical to Present at the LD Micro Virtual Invitational Conference on June 9, 2021

Rhea-AI Summary

Nemaura Medical (NASDAQ: NMRD) will present a corporate overview at the LD Micro Virtual Invitational Conference from June 8-10, 2021. CEO Faz Chowdhury, Ph.D., is scheduled to present on June 9 at 1:00 PM ET, Track 3. Investors can register to watch the presentation here. Nemaura specializes in non-invasive wearable devices for diabetes management, including the CE mark approved sugarBEAT® and the AI-enhanced proBEAT™.

News Market Reaction – NMRD

+22.70%

+22.70% Session move

In the trading session that priced this news, NMRD gained 22.70%, reflecting a significant positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Loughborough, England, June 01, 2021 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc. (NASDAQ: NMRD), a medical technology company focused on developing and commercializing non-invasive wearable diagnostic devices and supporting personalized lifestyle coaching programs, today announced that Chief Executive Officer Faz Chowdhury, Ph.D. will present a corporate overview at the three-day LD Micro Virtual Invitational Conference being held on June 8 – 10, 2021.

Dr. Chowdhury will deliver his corporate presentation on June 9 at 1:00pm ET, Track 3.

Investors can register to watch the presentation here.

Investors interested in scheduling a meeting with management should contact assistant@ldmicro.com.

About Nemaura Medical, Inc.

Nemaura Medical Inc. is a medical technology company developing and commercializing non-invasive wearable diagnostic devices. The company is currently commercializing sugarBEAT^® and proBEAT^™. sugarBEAT^®, a CE mark approved Class IIb medical device, is a non-invasive and flexible continuous glucose monitor (CGM) providing actionable insights derived from real time glucose measurements and daily glucose trend data, which may help people with diabetes and pre-diabetes to better manage, reverse, and prevent the onset of diabetes. Nemaura has submitted a PMA (Premarket Approval Application) for sugarBEAT^® to the U.S. FDA. proBEAT^™ combines non-invasive glucose data processed using artificial intelligence and a digital healthcare subscription service and has been launched in the U.S. as a general wellness product as part of its BEAT^®diabetes program.

The Company sits at the intersection of the global Type 2 diabetes market that is expected to reach nearly $59 billion by 2025, the $50+ billion pre-diabetic market, and the wearable health-tech sector for weight loss and wellness applications that is estimated to reach $60 billion by 2023.

For more information, please visit www.NemauraMedical.com.

Contact:

Jules Abraham
CORE IR
917-885-7378
julesa@coreir.com

FAQ

What is Nemaura Medical's presentation schedule for the LD Micro Virtual Conference?

Nemaura Medical's CEO, Faz Chowdhury, will present on June 9, 2021, at 1:00 PM ET, Track 3 during the LD Micro Virtual Invitational Conference.

Where can investors register to watch Nemaura Medical's presentation?

Investors can register to watch the presentation by visiting this link.

What products does Nemaura Medical offer for diabetes management?

Nemaura Medical offers sugarBEAT®, a CE mark approved continuous glucose monitor, and proBEAT™, which combines glucose data with a digital healthcare subscription service.